Structure−Activity Relationships of Novel Cyclic α-MSH/β-MSH Hybrid Analogues That Lead to Potent and Selective Ligands for the Human MC3R and Human MC5R
Authors:
- 23 July 2003
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (17) , 3728-3733
Abstract
It has been shown by extensive studies that α-MSH bioactivity is critically dependent on the core or central tetrapeptide sequence, His-Phe-Arg-Trp, however with poor selectivity for the human MC3R-MC5R. The structure−activity relationships study here is aimed at identifying lead structures or templates of this core sequence by the use of different conformational constraints that might impart changes in its topography and thus promote differences in potency and selectivity at these receptors. Our peptide library consists of a novel series of cyclic α-MSH analogues that have disulfide bridges between Cys or Cys-like residues at positions 4 and 10, giving rise to 23-membered rings fused at the C-terminal end with the C-terminal fragment of β-MSH (Pro-Pro-Lys-Asp). While such constraints of the peptide backbone with disulfide bridges of different chirality affect potency and selectivity at these receptors, further changes in the hydrophobicity at position 7 with either a d-Phe or d-Nal(2‘) and replacement of a His with a Pro in position 6 cause additional effects. Thus, the most interesting lead compounds that emerged from this study are (1) compound 5, Ac-c[Cys-Glu-His-d-Phe-Arg-Trp-d-Cys]-Pro-Pro-Lys-Asp-NH2 (IC50 = 10 nM), which is the first potent and highly selective antagonist ligand for the hMC5R (560-fold vs the MC3R and 1000-fold vs the MC4R); (2) compound 7, Ac-c[Cys-Glu-Pro-d-Nal(2‘)-Arg-Trp-Cys]-Pro-Pro-Lys-Asp-NH2 (IC50 = 31 nM), which is a highly selective antagonist analogue for the MC3R (560-fold vs the hMC4R and about 3000-fold vs the hMC5R; and (3) compound 9, Ac-c[Pen-Glu-His-d-Nal(2‘)-Arg-Trp-Cys]-Pro-Pro-Lys-Asp-NH2 (IC50 = 3 nM), which is more potent than 7 at the MC3R but not as selective.Keywords
This publication has 18 references indexed in Scilit:
- Designing peptide receptor agonists and antagonistsNature Reviews Drug Discovery, 2002
- Preparation of ‘side‐chain‐to‐side‐chain’ cyclic peptides by Allyl and Alloc strategy: potential for library synthesisChemical Biology & Drug Design, 2001
- Discovery of novel melanocortin4 receptor selective MSH analoguesBritish Journal of Pharmacology, 1998
- Use of Alloc-amino acids in solid-phase peptide synthesis. Tandem deprotection-coupling reactions using neutral conditionsTetrahedron Letters, 1997
- Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNAFEBS Letters, 1992
- Solid‐phase synthesis of bovine pancreatic trypsin inhibitor BPTI) and two analoguesInternational Journal of Peptide and Protein Research, 1992
- The Cloning of a Family of Genes That Encode the Melanocortin ReceptorsScience, 1992
- Regulation of the Synthesis of Steroidogenic Enzymes in Adrenal Cortical Cells by ACTHAnnual Review of Physiology, 1988
- .alpha.-Melanotropin: the minimal active sequence in the frog skin bioassayJournal of Medicinal Chemistry, 1987
- Solid‐phase synthesis of somatostatin and glucagon‐selective analogs in gram quantitiesBiopolymers, 1978